<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00206661</url>
  </required_header>
  <id_info>
    <org_study_id>308001</org_study_id>
    <secondary_id>91409</secondary_id>
    <secondary_id>Novel 6</secondary_id>
    <nct_id>NCT00206661</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease</brief_title>
  <official_title>Phase 1/2 Safety, Pharmacokinetic, and Pharmacodynamic Study of Sargramostim (LeukineÂ®) in Pediatric Patients With Active Crohn's Disease, With One-year Surveillance and Retreatment Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe pediatric Crohn's Disease response to sargramostim in
      patients with or without steroid therapy at two possible dosage levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE:
      This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer
      HealthCare, Inc.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the safety profile of sargramostim treatment with concomitant corticosteroid induction therapy</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetic, pharmacodynamics properties of sargramostim treatment with concomitant corticosteroid induction therapy</measure>
    <time_frame>Week 0, 1, and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of sargramostim treatment with concomitant corticosteroids as measured by the Pediatric Crohn's Disease Activity Index (PCDAI), Physician's Global Assessment (PGA), and IMPACT-III Questionnaire</measure>
    <time_frame>PCDAI, PGA: Week -1 to EOS; IMPACT-II: Week 0, 8 and EOS</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim (Leukine)</intervention_name>
    <description>4 mcg sargramostim with and without corticosteroids</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>BAY86-5326</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim (Leukine)</intervention_name>
    <description>6 mcg sargramostim with and without corticosteroids</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>BAY86-5326</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a parent or guardian able to provide written informed consent

          -  Be able to provide verbal or written assent depending on age

          -  Age 6 to 16 years

          -  Have confirmed diagnosis of Crohn's Disease at study time of study entry based on
             radiologic, endoscopic, or histologic evaluations

          -  Have a PCDAI score &gt;/= 30 points

          -  Have a negative serum pregnancy test within 7 days prior to receiving the first dose
             of sargramostim in female patients who, in the opinion of the investigator, are
             sexually active and of childbearing potential

          -  Be able to self-inject sargramostim or have a designee who can do so

          -  Available documentations of weight from 4 to 6 months prior to study entry

        Exclusion Criteria:

          -  Existing colostomy or ileostomy

          -  Immediate need of GI surgery for active GI bleeding, peritonitis, intestinal
             obstruction, or intra-abdominal or perianal abscess requiring surgical drainage

          -  GI surgery within 3 month prior to receiving the first dose of sargramostim

          -  Symptoms of bowel obstruction or confirmed evidence of a clinically significant
             stricture within the last 6 month that has not been surgically corrected

          -  Use of any of the following medications within 4 weeks prior to receiving the first
             dose of study drug: 6 mercaptopurine, azathioprine, cyclophosphamide, methotrexate,
             mycophenolate mofetil, tacrolimus, cyclosporine, or thalidomide

          -  Use of licensed/registered and/or experimental anti-tumor necrosis factor (TNF)
             therapy such as infliximab or adalimumab within 8 weeks prior to first dose of
             sargramostim

          -  Use of any investigational drug within 4 weeks or 5 half-lives (whichever is greater)
             prior to receiving the first dose of sargramostim

          -  Concurrent use of corticosteroid therapy for Crohn's Disease, which exceeds a dose of
             60 mg/day (or equivalent) of prednisone

          -  Inability to comply with protocol requirements or provide informed consent

          -  Presence of clinically important comorbid condition(s) unrelated to Crohn's Disease

          -  Prior use of recombinant human GM-CSF (sargramostim or molgramostim) or granulocyte
             colony-stimulating factor (G-CSF; filgrastim or pegfilgrastim)

          -  Current use of nutritional therapy (i.e., tube feeding or elemental/polymeric diet)
             which provides &gt; 50% of daily caloric intake
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118-5799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962-1956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

